The stock of Centessa Pharmaceuticals plc ADR (CNTA) has gone up by 8.75% for the week, with a 36.61% rise in the past month and a 85.33% rise in the past quarter. The volatility ratio for the week is 10.13%, and the volatility levels for the past 30 days are 8.36% for CNTA. The simple moving average for the past 20 days is 15.02% for CNTA’s stock, with a 66.14% simple moving average for the past 200 days.
Is It Worth Investing in Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Right Now?
The 36-month beta value for CNTA is at 1.42. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CNTA is 75.51M, and currently, shorts hold a 2.61% of that float. The average trading volume for CNTA on September 19, 2024 was 519.24K shares.
CNTA) stock’s latest price update
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA)’s stock price has gone rise by 4.52 in comparison to its previous close of 15.71, however, the company has experienced a 8.75% increase in its stock price over the last five trading days. globenewswire.com reported 2024-09-12 that BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an upsized underwritten public offering of 15,254,237 of American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $14.75 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $225 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about September 16, 2024, subject to customary closing conditions. Centessa has also granted the underwriters a 30-day option to purchase up to an additional 2,288,135 ADSs at the public offering price, less underwriting discounts and commissions.
Analysts’ Opinion of CNTA
Oppenheimer, on the other hand, stated in their research note that they expect to see CNTA reach a price target of $14. The rating they have provided for CNTA stocks is “Outperform” according to the report published on July 18th, 2024.
Jefferies gave a rating of “Buy” to CNTA, setting the target price at $11 in the report published on November 15th of the previous year.
CNTA Trading at 35.93% from the 50-Day Moving Average
After a stumble in the market that brought CNTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.65% of loss for the given period.
Volatility was left at 8.36%, however, over the last 30 days, the volatility rate increased by 10.13%, as shares surge +34.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +65.66% upper at present.
During the last 5 trading sessions, CNTA rose by +8.61%, which changed the moving average for the period of 200-days by +144.78% in comparison to the 20-day moving average, which settled at $14.49. In addition, Centessa Pharmaceuticals plc ADR saw 106.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CNTA starting from Weinhoff Gregory M, who sale 30,000 shares at the price of $17.00 back on Sep 10 ’24. After this action, Weinhoff Gregory M now owns 223,369 shares of Centessa Pharmaceuticals plc ADR, valued at $510,000 using the latest closing price.
SAHA SAURABH, the Chief Executive Officer of Centessa Pharmaceuticals plc ADR, sale 175,000 shares at $16.52 during a trade that took place back on Sep 10 ’24, which means that SAHA SAURABH is holding 776,924 shares at $2,891,822 based on the most recent closing price.
Stock Fundamentals for CNTA
Current profitability levels for the company are sitting at:
- -22.54 for the present operating margin
- 0.86 for the gross margin
The net margin for Centessa Pharmaceuticals plc ADR stands at -22.81. The total capital return value is set at -0.42. Equity return is now at value -55.88, with -39.78 for asset returns.
Based on Centessa Pharmaceuticals plc ADR (CNTA), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -1.94. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is -15.33.
Currently, EBITDA for the company is -171.13 million with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of 263.95. The receivables turnover for the company is 0.15for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.29.
Conclusion
In conclusion, Centessa Pharmaceuticals plc ADR (CNTA) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
